Great Lakes Advisors LLC Purchases New Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Great Lakes Advisors LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 169,557 shares of the specialty pharmaceutical company's stock, valued at approximately $6,131,000. Great Lakes Advisors LLC owned 0.31% of Supernus Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Exchange Traded Concepts LLC increased its stake in shares of Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock valued at $800,000 after buying an additional 560 shares during the period. HighTower Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock valued at $330,000 after buying an additional 624 shares during the period. Rhumbline Advisers increased its stake in shares of Supernus Pharmaceuticals by 0.5% during the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock valued at $6,236,000 after buying an additional 800 shares during the period. Quartz Partners LLC grew its stake in Supernus Pharmaceuticals by 3.0% in the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company's stock valued at $1,031,000 after purchasing an additional 820 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares during the last quarter.

Remove Ads

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded up $0.09 during trading on Friday, hitting $31.26. The company's stock had a trading volume of 526,106 shares, compared to its average volume of 564,157. The company has a market cap of $1.74 billion, a PE ratio of 29.22 and a beta of 0.83. The business's 50 day simple moving average is $36.22 and its 200-day simple moving average is $35.16. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insiders Place Their Bets

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SUPN. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 8th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.